Ab­b­Vie eyes can­cer, im­munol­o­gy in lat­est pro­tein degra­da­tion pact, hand­ing Fron­tier Med­i­cines $55M up­front

Two years af­ter tip­toe­ing in­to the pro­tein degra­da­tion space with a dis­cov­ery pact cen­tered on neu­rode­gen­er­a­tion, Ab­b­Vie is wad­ing deep­er to ex­plore the more com­mon …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER